Date: 2014-09-02
Type of information: Nomination
Compound:
Company: Epizyme (USA - CO)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease:
Details: * On September 2, 2014, Epizyme, a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced that Jason Rhodes , President and Chief Financial Officer, has resigned from the company, effective September 30, 2014 . Mr. Rhodes , who has served on Epizyme\'s leadership team since 2010, will be joining a venture capital firm. The Company has a search underway to identify a new chief financial officer, and Mr. Rhodes has agreed to assist Epizyme in an advisory capacity through the end of 2014 to ensure a smooth transition.
Financial terms:
Latest news:
